Regulators

A CE Mark Is Not Access

Europe Opens the SMA Gene-Therapy Door Wider

ALS Needs Proof, Not Just Another Biomarker

The Transplant Is Not the Finish Line

For Pompe Infants, Time Is the Comparator

Global cardiovascular policy shifts accelerate, but diverging strategies expose uneven progress

Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach

Eight Patients Cannot Solve Alzheimer’s. They Can Tell Us What the Next Trial Must Prove.

Deep learning uncovers a new ECG biomarker for sudden cardiac death
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
